市场见解

The Pro Medicus (ASX:PME) share price has dropped 8% in 3 days. What’s going on?

The dip in Pro Medicus shares is accompanied by a sector-wide sell-off.
The post The Pro Medicus (ASX:PME) share price has dropped 8% in 3 days. What’s going on? appeared first on The Motley Fool Australia. –

Shares in Pro Medicus Limited (ASX: PME) have had a poor run these past few days after falling off a high of $62.48 on 30 November.

There’s been no market-sensitive information out of the Pro Medicus camp in this time. But that hasn’t stopped investors selling off shares violently. The company opened Monday’s session at $55.93 after pre-market trading.

What’s up with Pro Medicus shares?

Despite the recent weakness, shares in the health imaging IT provider were a standout performer in November. They closed out the month 17% in the green – well ahead of most healthcare majors.

However, the dip in Pro Medicus shares is accompanied by a sector-wide sell-off. This sell-off has been in situ since we rolled into December.

For instance, the S&P/ASX 200 Health Care Index (XHJ) has slipped 5% since the end of November, and shows no sign of slowing from the open today.

Concern around the Omicron COVID-19 variant and frothy share markets around the world has many investors taking risk off the table and seeking more defensive positions in safer assets, according to recent analysis from Goldman Sachs and JP Morgan.

Goldman has even lowered its 2022 US GDP forecasts from 4.2% to 3.8%, citing risks and potential impacts of the new strain, according to reporting from Bloomberg Intelligence.

This activity appears to have boded poorly for ASX health care shares, Pro Medicus included.

Although, the team at investment bank Citi reckons the pullback in the company’s share price is warranted.

The firm rates Pro Medicus a sell at $45/share and reckons that investors could be overly optimistic in their growth projections for the company.

Citi notes the presence of many substitute products from Pro Medicus’ competitors that could originate in future. This poses a threat to the company’s profits and could compress its margins going forward, the broker says.

In the absence of any price-sensitive information out of the company’s camp lately, it appears that weakness in the wider sector has spilled over into names like Pro Medicus as a negative catalyst to its share price.

Pro Medicus share price snapshot

In the past 12 months the Pro Medicus share price has climbed more than 90%. Pro Medicus shares have rallied 67% this year to date.

However, they have taken a backward step in the last month and are almost 7% in the red. The Pro Medicus share price has fallen 6.65% in just the last week of trading.

The post The Pro Medicus (ASX:PME) share price has dropped 8% in 3 days. What’s going on? appeared first on The Motley Fool Australia.

Should you invest $1,000 in Pro Medicus right now?

Before you consider Pro Medicus, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Pro Medicus wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Here are the top 10 ASX shares today

These were the 5 best performing ASX healthcare shares in November

ASX 200 (ASX:XJO) midday update: ANZ hit with class action, GUD sinks

5 things to watch on the ASX 200 on Tuesday

Leading brokers name 3 ASX shares to sell today

The author has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia has recommended SDI Limited and Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

随时随地,交易世界!

移动APP平台,拥有 12 个市场的 50,000 多种全球上市证券(全球市值超过 70%),直接在您的 Android 或 iOS 设备上即可操作。

与独有的交易理念和投资分析工具相结合,帮助您在我们 12 个全球市场中的几乎所有金融工具上找到可操作的见解,从而帮助您优化交易策略。

推荐给您的朋友

向您的朋友推荐Monex并赠予他们免费使用我们交易工具的机会

我们尊重您的隐私,只会向您的朋友发送一封邮件 

与您的朋友分享

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!